The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) ...

Consensus for Q4 revenue is $12.94M. Expects to report cash and cash equivalents at December 31, 2024, of $400M vs. $271.8M a year ago. “2024 ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of ...

Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the ...